Übersicht – Aktueller Stand der Systemtherapie beim metastasierten Prostatakarzinom

Patienten mit der Erstdiagnose eines metastasierten Prostatakarzinoms können mit einer alleinigen antiandrogenen Therapie palliativ über viele Jahre in einem stabilen Krankheitszustand bei guter Lebensqualität geführt werden. Allerdings entwickeln diese Patienten im Mittel nach 3–4 Jahren einen erneuten Krankheitsprogress, der mit einem Anstieg des prostataspezifischen Antigens (PSA) einhergeht. Die vorliegende Arbeit gibt eine Übersicht über die aktuellen Therapieoptionen und -sequenzen des metastasierten Prostatakarzinoms.

• Literatur

• 1 Sweeney C. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 2014; 32 (Suppl. 05) abstr LBA2
• 2 Ohlmann CH, Duensing S, Eichenauer R et al. Metastasized prostate cancer: Position paper on the use of chemotherapy. Der Urologe Ausg A 2015; in print
• 3 James N. Docetaxel and / or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 2015; 33 suppl: abstr 5001
• 4 Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Europ Urol 2014; 65: 467-479
• 5 Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992
• 6 Ryan CJ, Smith MR, Fizazi K et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncol 2015; 16: 152-160
• 7 Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med 2012; 367: 1187-1197
• 8 Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. New Engl J Med 2014; 371: 1755-1756
• 9 Higano C. Response rates and outcomes with enzalutamide for patients with metastatic castration resistant prostate cancer and visceral disease in the PREVAIL-study. Annals Oncol 2014; 25 (Suppl. 04) iv255-iv279
• 10 Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004; 351: 1502-1512
• 11 Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013; 14: 117-124
• 12 Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol 2011; 7: 497-506
• 13 Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New Engl J Med 2014; 371: 1028-1038
• 14 Angelergues A. Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2014; 32 (Suppl. 04) abstr 282
• 15 Pezaro CJ, Omlin AG, Altavilla A et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Europ Urol 2014; 66: 459-465